These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 1647195)
1. Intravenous administration of amphotericin B entrapped in liposomes: induction of high serum levels of TNF alpha. Sculier JP; Body JJ Ann Oncol; 1991 Feb; 2(2):141-4. PubMed ID: 1647195 [TBL] [Abstract][Full Text] [Related]
2. Cyclophosphamide, doxorubicin and vincristine with amphotericin B in sonicated liposomes as salvage therapy for small cell lung cancer. Sculier JP; Klastersky J; Libert P; Ravez P; Brohee D; Vandermoten G; Michel J; Thiriaux J; Bureau G; Schmerber J Eur J Cancer; 1990; 26(8):919-21. PubMed ID: 2171602 [No Abstract] [Full Text] [Related]
3. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses. Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698 [TBL] [Abstract][Full Text] [Related]
4. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer]. Saito H; Kawatsu H; Saka H; Yamamoto M; Takagi E; Tsunekawa H; Kawachi H; Nagura E; Sakai S; Nishiwaki K Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000 [TBL] [Abstract][Full Text] [Related]
5. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy. Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527 [TBL] [Abstract][Full Text] [Related]
7. A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer. Leighl NB; Burkes RL; Dancey JE; Lopez PG; Higgins BP; David Walde PL; Rudinskas LC; Rahim YH; Rodgers A; Pond GR; Shepherd FA Clin Lung Cancer; 2003 Sep; 5(2):107-12. PubMed ID: 14596693 [TBL] [Abstract][Full Text] [Related]
8. Use of cisplatin, cyclophosphamide, vincristine, and doxorubicin for the treatment of non-small cell lung cancer. Lindgren D; Cadman E; Erichson R; Grann V; Sachs K Cancer Treat Rep; 1984 Sep; 68(9):1159-61. PubMed ID: 6090015 [TBL] [Abstract][Full Text] [Related]
9. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer. Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808 [TBL] [Abstract][Full Text] [Related]
10. Treatment of small cell lung cancer with cyclophosphamide, adriamycin and vincristine (CAV) combination therapy: experience at University Hospital, Kuala Lumpur, Malaysia. Lee SM Singapore Med J; 1990 Aug; 31(4):317-20. PubMed ID: 2175049 [TBL] [Abstract][Full Text] [Related]
11. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer. Erkişi M; Unsal M; Tunali C; Burgut R; Doran F J Chemother; 1993 Feb; 5(1):56-9. PubMed ID: 8384659 [TBL] [Abstract][Full Text] [Related]
12. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. Goodman GE; Crowley JJ; Blasko JC; Livingston RB; Beck TM; Demattia MD; Bukowski RM J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194 [TBL] [Abstract][Full Text] [Related]
13. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer. Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Kamei H; Horiguchi T; Kodani T; Maeda T; Tabata M; Shibayama T Cancer; 1993 Sep; 72(5):1597-601. PubMed ID: 8394202 [TBL] [Abstract][Full Text] [Related]
14. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group. Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577 [TBL] [Abstract][Full Text] [Related]
15. Doxorubicin and 4'-epidoxorubicin in combination chemotherapy of extensive small cell lung cancer. Nikkanen TA; Jakobsson M; Järvinen M; Liippo K; Ojala A; Paloheimo S; Nordman E Acta Oncol; 1988; 27(1):75-6. PubMed ID: 2835069 [No Abstract] [Full Text] [Related]
16. [Chemotherapy of small cell lung cancer]. Komiya T; Takada M Gan To Kagaku Ryoho; 1996 Aug; 23(9):1116-23. PubMed ID: 8751797 [TBL] [Abstract][Full Text] [Related]